HighTower Advisors
CKPT

HighTower Advisors’s Checkpoint Therapeutics CKPT Stock Holding History

HighTower Advisors’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,000
Closed -$7.8K – 3796
2024
Q4 		$7.8K Buy
+6,000
New +$20.3K ﹤0.01% 3598

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

HighTower Advisors's CKPT Position: Q1 2025 in Review

HighTower Advisors sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 8,500 shares — an estimated $27.2K sold.

HighTower Advisors first reported a position in CKPT in Q4 2024 and held it in 1 quarter. The position peaked at $27.2K in Q4 2024. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • HighTower Advisors reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HighTower Advisors sold 8,500 Checkpoint Therapeutics shares in Q1 2025, an estimated $27.2K.
  • HighTower Advisors first reported a position in Checkpoint Therapeutics in Q4 2024 and held it in 1 quarter.
  • HighTower Advisors's Checkpoint Therapeutics position peaked at $27.2K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on HighTower Advisors's 13F filing for Q1 2025, filed 13 May 2025.